Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy

被引：30

作者：

Lozano, HF ^{[1
]}

Conde, CA ^{[1
]}

Florin, T ^{[1
]}

Lamas, GA ^{[1
]}

机构：

[1] Mt Sinai Med Ctr, Div Cardiol, Miami Beach, FL 33140 USA

来源：

HEART RHYTHM | 2005年 / 2卷 / 09期

关键词：

atrial fibrillation; angiotensin-converting enzyme inhibitor; angiotensin receptor blocker; statin; renin-angiotensin system;

D O I：

10.1016/j.hrthm.2005.05.020

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Atrial fibrillation is one of the most frequent heart rhythm disturbances found in clinical practice. Anticoagulation, rate control, cardioversion, and ablative procedures have been the mainstay of treatment. The frequent recurrence of atrial fibrillation and the side effects when antiarrhythmic drugs are used have led to dissatisfaction with available treatment of this arrhythmia. Pharmacologic therapy with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, statins, and perhaps aldosterone and calcium channel blockers may have a role in the prevention of atrial fibrillation onset and recurrence. We summarize the possible biologic mechanisms and the clinical observations supporting the use of nonantiarrhythmic medications in the prevention of atrial fibrillation.

引用

页码：1000 / 1007

页数：8

共 44 条

[1] Frequency of elevation of C-reactive protein in atrial fibrillation [J].

Anderson, JL ;

Maycock, CAA ;

Lappé, DL ;

Crandall, BG ;

Horne, BD ;

Bair, TL ;

Morris, SR ;

Li, QY ;

Muhlestein, JB .

AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (10) :1255-1259

[2] Atrial fibrillation: the remodelling phenomenon [J].

Botto, GL ;

Luzi, M ;

Sagone, A .

EUROPEAN HEART JOURNAL SUPPLEMENTS, 2003, 5 (0H) :H1-H7

[3] Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways [J].

Cardin, S ;

Li, DS ;

Thorin-Trescases, N ;

Leung, TK ;

Thorin, E ;

Nattel, S .

CARDIOVASCULAR RESEARCH, 2003, 60 (02) :315-325

[4] C-reactive protein elevation in patients with atrial arrhythmias - Inflammatory mechanisms and persistence of atrial fibrillation [J].

Chung, MK ;

Martin, DO ;

Sprecher, D ;

Wazni, O ;

Kanderian, A ;

Carnes, CA ;

Bauer, JA ;

Tchou, PJ ;

Niebauer, MJ ;

Natale, A ;

Van Wagoner, DR .

CIRCULATION, 2001, 104 (24) :2886-2891

[5]

COLIVICCHI F, 2004, HEART RHYTHM S1, V1, pS168

[6] VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF study) [J].

De Simone, A ;

De Pasquale, M ;

De Matteis, C ;

Canciello, M ;

Manzo, M ;

Sabino, L ;

Alfano, F ;

Di Mauro, M ;

Campana, A ;

De Fabrizio, G ;

Vitale, DF ;

Turco, P ;

Stabile, G .

EUROPEAN HEART JOURNAL, 2003, 24 (15) :1425-1429

[7] Effect of verapamil on secondary cardioversion in patients with early atrial fibrillation recurrence after electrical cardioversion [J].

De Simone, A ;

Turco, P ;

De Matteis, C ;

La Rocca, V ;

Nocerino, P ;

Greco, L ;

Astarita, C ;

Messina, V ;

Rotunno, R ;

Iaconelli, G ;

Stabile, E ;

Stabile, G .

AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (02) :185-+

[8] Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation [J].

Dernellis, J ;

Panaretou, M .

EUROPEAN HEART JOURNAL, 2004, 25 (13) :1100-1107

[9] Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial [J].

Fetsch, T ;

Bauer, P ;

Engberding, R ;

Koch, HP ;

Lukl, J ;

Meinertzf, T ;

Oeff, M ;

Seipel, L ;

Trappe, HJ ;

Treese, N ;

Breithardt, G .

EUROPEAN HEART JOURNAL, 2004, 25 (16) :1385-1394

[10] Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation [J].

Gensini, F ;

Padeletti, L ;

Fatini, C ;

Sticchi, E ;

Gensini, GF ;

Michelucci, A .

PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2003, 26 (01) :295-298

← 1 2 3 4 5 →